[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tan Tock Seng Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":536},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,49,81,106,137,165,189,215,238,263,289,312,339,360,380,396,417,436,461,489,513],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100612613","aviga3-cohort-20-100612613",false,"NCT07255859","AVIGA3 (Cohort 2.0)","AVIGA3: Using an 'Automated Vision Assessment and Impairment Detection Through Gaze Analysis' Through a Longitudinal, Open-labelled, Randomized Clinical Trial to Monitor Recurrence of Aged-related Macular Degeneration in a Home-based Setting (Cohort 2.0).","AVIGA3","Inclusion criteria\n\n1. Subjects in the age group ≥ 50 to 99 years old.\n2. Both genders\n3. Able to understand verbal spoken instructions in British\u002FAmerican English, Chinese or Bahasa Melayu and demonstrate device functionality and implementation.\n4. Able to turn on and connect the web-camera to a computer independently or with the help of family.\n5. Subjects undergoing treatment for Wet-AMD without any signs and symptoms of recurrence of active AMD (AMD recurrence: choroidal neovascularisation, intraretinal or subretinal fluid is present) with OCT lesion fluid volume more than 2 mm3 or ILM height more than 250µm.\n6. Ability to comply with the study protocol, in the investigator's judgment.\n7. Subjects must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments.\n\nExclusion criteria\n\n1. Unable to understand verbal spoken instructions and demonstrate device functionality and implementation.\n2. Unable to turn on and connect the web-camera to a computer independently.\n3. Any ocular surgery in the previous 3 months, or vitrectomy in the previous 12 months\n4. Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye\n5. Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study\n6. Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye.\n7. History of idiopathic or autoimmune-associated uveitis in either eye\n8. Active ocular inflammation or suspected or active ocular or periocular infection in either eye.","ALL","50 Years","99 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate the AVIGA system through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.",[28],"Maculopathy",[30,31,32,33,34,35],"aged-related macular degeneration","choroidal neovascularization","wet aged-related macular degeneration","gaze tracking","dry aged-related macular degeneration","maculopathy","RECRUITING","2026-06-21",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":40},"2025-06-16",{"date":44,"type":22},"2027-12-31",{"name":46,"class":47},"Tan Tock Seng Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":48},"100454575","phase-4-early-oral-switch-for-uncomplicated-gram-negative-bacteraemia-100454575","NCT05199324","Early Oral Switch for Uncomplicated Gram-negative Bacteraemia","Early Oral Step-down Antibiotic Therapy Versus Continuing Intravenous Therapy for Uncomplicated Gram-negative Bacteraemia (the INVEST Trial)","INVEST","Inclusion Criteria:\n\n1. One or more set(s) of blood cultures positive for Gram-negative bacteria (GNB) associated with evidence of infection\n2. Able to be randomised within 72 hours of index blood culture collection\n3. Age ≥18 years (≥21 in Singapore)\n4. Latest Pitt bacteraemia score \\\u003C4\n5. Patient or legal representative is able to provide informed consent\n\nExclusion Criteria:\n\n1. Established uncontrolled focus of infection, including but not limited to:\n\n   * Undrained abdominal abscess, deep seated intra-abdominal infection and other unresolved abdominal sources requiring surgical intervention\n   * Central nervous system abscess (patients with focal neurology should have cranial CT prior to enrolment)\n   * Undrained moderate-to-severe hydronephrosis\n2. Complicated infections, including but not limited to:\n\n   * Necrotising fasciitis\n   * Empyema\n   * Central nervous system infections and meningitis\n   * Endocarditis \u002F endovascular infections\n3. Septic shock as defined by systolic blood pressure \\\u003C90 or mean arterial pressure \\\u003C70 mmHg despite adequate fluid resuscitation or need for inotropic\u002Fvasopressor support\n4. Polymicrobial bacteraemia involving Gram-positive pathogens or anaerobes (defined as either growth of 2 or more different microorganism species in the same blood culture, or growth of different species in 2 or more separate blood cultures within the same episode \\[\\\u003C48 hours\\] and with clinical or microbiological evidence of the same source)\n5. Bacteraemia is due to a vascular catheter or intravascular materials (e.g. pacing wire, vascular graft) that cannot be removed\n6. Specific Gram-negative pathogens that cannot be effectively treated with fluoroquinolones or trimethoprim-sulfamethoxazole, including but not limited to, Burkholderia spp. and Brucella spp.\n7. Index GNB with resistance to fluoroquinolones AND trimethoprim-sulfamethoxazole\n8. Hypersensitivity to fluoroquinolones AND sulphur drugs as defined by history of rash, urticaria, angioedema, bronchospasm, circulatory collapse or significant adverse reaction following prior administration\n9. Unable to consume or absorb oral medications for any reason or unsuitable for ongoing IV therapy (e.g. no intravenous access)\n10. Severely immunocompromised in the opinion of the treating doctor, including but not limited to, medical conditions such as:\n\n    * Active leukaemia or lymphoma\n    * Aplastic anaemia\n    * Bone marrow transplant within two years of transplantation or transplants of longer duration still on immunosuppressive drugs or with graft-versus-host disease\n    * Congenital immunodeficiency\n    * HIV\u002FAIDS with CD4 lymphocyte count \\\u003C200\n    * Neutropenia or expected post-chemotherapy neutropenia within 14 days from the time of screening, defined as absolute neutrophil count \\\u003C 500 cells\u002FμL\n11. Women who are known to be pregnant or breast-feeding\n12. Treatment is not with intent to cure the infection (i.e. palliative care)\n13. Unable to collect patient's follow-up data for at least 30 days post-randomisation for any reason\n14. Treating doctor deems enrolment into the trial is not in the best interest of the patient\n15. Previous enrolment in this trial","18 Years",{"count":59,"type":22},720,[61],"PHASE4","Current management of uncomplicated Gram-negative bacteraemia entails prolong intravenous (IV) antibiotic therapy with limited evidence to guide oral conversion. This trial aim to evaluate the clinical efficacy and economic impact of early switch to oral antibiotics (within 72 hours from index blood culture collection) versus continuing standard of care IV therapy (for at least another 24 hours post-randomisation) for clinically stable \u002F non-critically ill inpatients with uncomplicated Gram-negative bacteraemia.",[64],"Gram-negative Bacteraemia",[66,67,68,69,70,71,72],"uncomplicated bacteraemia","gram-negative bacteria","early oral switch","antibiotics","fluoroquinolones","ciprofloxacin","trimethoprim-sulfamethoxazole","2026-04-13",{"date":75,"type":40},"2026-04-16",{"date":77,"type":40},"2022-06-03",{"date":79,"type":22},"2026-07",{"name":46,"class":47},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":48},"100630239","video-based-intervention-to-reduce-anxiety-in-patients-undergoing-elective-pci-100630239","NCT07485088","Video-based Intervention to Reduce Anxiety in Patients Undergoing Elective PCI","Effect of a Nurse-led Video-based Educational Intervention on Anxiety Among Hospitalised Patients Undergoing Elective Percutaneous Coronary Intervention: a Non-randomised Controlled Study","Inclusion Criteria:\n\n* adults scheduled for elective percutaneous coronary intervention\n* voluntary participation\n* ability to understand english\n* age 21 and above\n\nExclusion Criteria:\n\n* patients participating in other studies\n* outpatient PCI, urgent or emergency PCI\n* medically unstable\n* cognitive impairment",true,"21 Years",{"count":91,"type":22},144,[25],"This study aims to evaluate the effectiveness of a video-based educational intervention in reducing anxiety among hospitalised patients scheduled for elective percutaneous coronary intervention (PCI). Participants will be assigned to either a video intervention group or a control group without randomisation. The intervention group will receive a structured educational video related to the PCI procedure, while the control group will receive usual care. Anxiety levels will be measured using the State-Trait Anxiety Inventory at baseline and after the intervention to determine whether the video intervention reduces anxiety before the procedure.",[95,96,97],"Procedural Anxiety","Coronary Artery Disease","Percutaneous Coronary Intervention Patients","2026-03-19",{"date":100,"type":40},"2026-03-24",{"date":102,"type":22},"2026-03-16",{"date":104,"type":22},"2027-06",{"name":46,"class":47},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":48},"100624657","a-controlled-human-infection-model-of-dengue-100624657","NCT07412483","A Controlled Human Infection Model of Dengue","DEN-CHIM-01","Inclusion Criteria:\n\n1. An informed consent form (ICF) has been signed and dated by the participant, an investigator, and a witness\n2. Adult, aged between 21 and 45 years, inclusive (at the time of consent)\n3. No known history of prior dengue, zika or other Orthoflavivirus infection\n4. No history of prior dengue, yellow fever, Japanese encephalitis virus, or other Orthoflavivirus vaccination\n5. Sero-suitable based on the pre-screening serology result\n6. a Female participants must be willing and able to use contraception from 2 weeks before the scheduled date of viral challenge until 1 month after receipt of the final dose of study virus. Negative urine pregnancy tests will be required at screening, and on admission to the quarantine unit a negative serum beta human chorionic gonadotropin (β-hCG) is required prior to inoculation.\n\n6b Male participants who are willing to use one of the contraception methods described in the study protocol, from the date of viral challenge, for 1 month. In addition to the contraceptive requirements above, male participants must agree not to donate sperm following discharge from quarantine until 1 month after the date of viral challenge.\n\n7 In good health with no history of clinically significant medical conditions (as described in Exclusion criteria) that would interfere with subject safety, as defined by medical history, physical examination and routine laboratory tests, ECG, and Chest X-Ray and determined by the Investigator at an admission evaluation.\n\n8 Willing and able to commit to participation in the study.\n\nExclusion Criteria:\n\n1. History or evidence of any clinically significant or currently active neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease.\n2. History of active depression and\u002For anxiety with associated severe psychiatric comorbidities, for example psychosis.\n3. Behavioural, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the requirements of the study protocol.\n4. Significant history or presence of drug or alcohol misuse\n5. History of anaphylaxis and\u002For a history of severe allergic reaction or significant intolerance to any food or drug, as assessed by the PI.\n6. Family history of 1st degree relative aged 50 years or less with sudden cardiac or unexplained death\n7. A total body weight of ≤ 45kg and a Body Mass Index (BMI) ≤18 kg\u002Fm2 and ≥30 kg\u002Fm2.\n8. Venous access deemed inadequate for the phlebotomy demands of the study.\n9. Any clinically significant abnormal finding on screening biochemistry, haematology and microbiology blood tests or urinalysis apart from minor deviations which are clinically acceptable and approved by the investigator.\n\nAny of the following:\n\n* Elevated HbA1C\n* Positive HIV, active\u002Fchronic hepatitis B or hepatitis C test. 10 Twelve-lead ECG recording with clinically relevant abnormalities as judged by the study investigator.\n\n  11 Receipt of a live vaccine within 60 days prior to the planned date of viral challenge, a non-live vaccine within 30 days prior to the planned date of viral challenge or intention to receive any vaccination(s) before the day 28 follow-up visit.\n\n  12 Previous receipt of a flavivirus vaccine (licensed or experimental). 13 Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 3 months prior to the planned date of viral challenge or planned during the 3 months after the final visit.\n\n  14 Medications:\n  1. Receipt of any investigational drug within 3 months prior to the planned date of viral challenge\n  2. Receipt of systemic (intravenous and\u002For oral) glucocorticoids or systemic antiviral drugs within 6 months prior to the planned date of viral challenge.\n  3. Over the counter medications (e.g., paracetamol or ibuprofen) where the dose taken over the preceding 7 days prior to the planned date of viral challenge had exceeded the maximum permissible 24-hour dose (e.g., \\>4g per day of paracetamol over the preceding week).\n  4. Participants who have received any systemic chemotherapy agent, immunoglobulins, or other cytotoxic or immunosuppressive drugs at any time.\n\n  15 Participant is mentally or legally incapacitated in the opinion of the Investigator.\n\n  16 Females who:\n  1. Are breastfeeding within 6 months of study commencement, or\n  2. Had been pregnant within 6 months prior to the study, or\n  3. Had a positive pregnancy test at any point during screening or prior to inoculation with challenge virus 17 Anyone who is first degree related to anyone who is a delegated member of the research team.\n\n  18 Any other reason that the Investigator considered made the participant unsuitable to participate.\n\n  19 Presence of symptoms and\u002For fever (defined as participant presenting with a temperature reading of \\>37.9ºC) suggesting an infection at pre-challenge on Day 0.","45 Years",{"count":115,"type":22},5,[25],"This study aims to conduct a safe human infection challenge using an attenuated serotype DEN3 dengue virus in adult volunteers. The clinical, viral and immune response characteristics of the model will be analysed to understand the pathophysiology of dengue fever. This data will be used to inform future studies, including a planned follow up study (DEN-CHIM-02) which will investigate the efficacy of an investigational dengue vaccine at protecting against DEN3 infection.\n\nStudy conditions that result in a safe, reproducible infection in ≥80% of research participants (attack rate) with the DEN3 challenge agent have been identified during studies conducted by our collaborators in the US. This includes the inoculum dose, safety monitoring, and necessary participant pre-screening to exclude prior Orthoflavivrus infection or vaccinations.\n\nStudy objectives are to:\n\n1. Establish in seronegative volunteers in Singapore a safe DENV controlled human infection (CHI) model, with an infection rate of ≥80%, suitable for future studies of interventions.\n2. Characterise the clinical, haematological and virological response following controlled inoculation of the attenuated DEN3 challenge agent.\n3. Conduct deep immunophenotyping to understand the cellular, humoral and innate immune response to dengue infection.\n4. Explore the longitudinal immune response in the 3 years after challenge, including following subsequent dengue vaccination.",[119],"Dengue",[121,122,123,124,125,126,127,128],"Human challenge study","controlled human infection model","dengue virus serotype 3","rDEN3delta30","dengue infection","dengue viremia","haematological response to dengue infection","neutralising antibodies to DEN-3","2026-02-11",{"date":131,"type":40},"2026-02-17",{"date":133,"type":22},"2026-03",{"date":135,"type":22},"2029-04",{"name":46,"class":47},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":154,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":164,"locationsCount":48},"100624817","effectiveness-of-an-web-application-in-enhancing-informal-caregivers-nasogastric-tube-feeding-competency-100624817","NCT07414563","Effectiveness of an Web Application in Enhancing Informal Caregivers' Nasogastric Tube Feeding Competency","Effectiveness of an Nasogastric Web Application in Reducing Time to Achieve Nasogastric Tube Feeding Competency Among Informal Caregivers","Caregivers who will receive standard face-to-face training\n\nInclusion Criteria:\n\n* Individual who has been identified by the healthcare team to undergo caregiver training for nasogastric feeding to assist a patient with nutritional needs.\n* No prior training or experience in nasogastric feeding.\n* Potentially able to complete course of caregiver training for nasogastric feeding in the hospital of enrolment.\n* Aged 21 and above.\n\nExclusion Criteria:\n\n* Caregivers who are cognitively impaired.\n* Have received prior training for nasogastric feeding.\n* Will not be able to complete their course of caregiving training for nasogastric feeding in the hospital of enrolment.\n\nCaregivers who will receive standard face-to-face training plus access to the web application\n\nInclusion Criteria:\n\n* Individual who has been identified by the healthcare team to undergo caregiver training for nasogastric feeding to assist a patient with nutritional needs.\n* No prior training or experience in nasogastric feeding.\n* Potentially able to complete course of caregiver training for nasogastric feeding in the hospital of enrolment.\n* Have the basic literacy skills to use the nasogastric tube web application.\n* Able to access and use the nasogastric web application over the course of their training in nasogastric tube feeding to support their learning.\n* Aged 21 and above.\n\nExclusion Criteria:\n\n* Caregivers who are cognitively impaired.\n* Have received prior training for nasogastric feeding.\n* Will not be able to complete their course of caregiving training for nasogastric feeding in the hospital of enrolment.\n* Have no or limited literacy ability to use the nasogastric web application\n* Unable to access and use the nasogastric web application over the course of their training in nasogastric tube feeding.\n\nPatients\n\nInclusion Criteria:\n\n* Aged 50 years and above.\n* Patient whose caregiver has been identified to undergo nasogastric tube feeding training to support their nutritional needs.\n* Has mental capacity as per the approved documentation of capacity form or has a legal representative willing to provide consent to allow study team to extract medical records.",{"count":145,"type":22},136,[25],"The goal of this trial is to determine whether adding a nasogastric tube web application to standard face-to-face caregiver training helps informal caregivers learn nasogastric tube feeding more quickly than standard training alone.\n\nThe main question is:\n\nDoes the use of a nasogastric tube web application alongside standard face-to-face caregiver training shorten the time required for caregivers to learn nasogastric tube feeding, compared with standard training alone?\n\nResearchers will compare two groups: caregivers who receive standard face-to-face training plus access to the web application and caregivers who only receive standard face-to-face training to see who will learn nasogastric tube feeding more quickly.\n\nParticipants will:\n\n* Receive either standard face-to-face training plus the web application or standard face-to-face training alone when identified for nasogastric tube feeding training.\n* Have their time taken to learn nasogastric tube feeding recorded.",[149,150,151,152,153],"Nasogastric Feeding","Training Family Caregivers","Family Caregivers","Informal Caregiver","Dysphagia",[155,156,151,157],"Nasogastric Tube Feeding","Caregiver Training","Web Application","NOT_YET_RECRUITING","2026-02-10",{"date":131,"type":40},{"date":133,"type":22},{"date":163,"type":22},"2026-09",{"name":46,"class":47},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":48},"100612727","pilot-study-of-normative-range-of-field-of-binocular-single-vision-in-adults-in-singapore-100612727","NCT07257341","Pilot Study of Normative Range of Field of Binocular Single Vision in Adults in Singapore","NORVIBAS","Inclusion Criteria:\n\n* Age: 21 to 59 years old\n* Gender: Males or females\n* Ethnicity: Asian descent.\n* Language comprehension: Able to understand verbal spoken instructions in:\n\n  • British\u002FAmerican English\n  * Mandarin Chinese\n  * Bahasa Melayu\n* Protocol compliance: Ability to comply with the study protocol, as determined by the investigator's judgment\n* Consent capacity: Must be able to understand and provide informed consent, with signed informed consent form required before any study assessments\n\nExclusion Criteria:\n\n\\- Communication barrier: Unable to understand verbal spoken instructions\n\n* Medical history:\n\n  * Any facial trauma\n  * Any ocular trauma\n  * Any head trauma\n  * Any history of ocular disease\n  * Any history of ocular surgery\n  * Systemic condition(s)\n* Near visual acuity:\n\n  o Right eye \\& Left eye monocularly, binocularly unaided near vision: worse than N6 at 40cm from participant's nose\n* Ocular alignment:\n\n  o Prism cover test at near (30cm) of equal or greater than 10 prism diopters at these positions of gaze:\n  * Primary gaze\n  * Right gaze\n  * Left gaze\n  * Up gaze\n  * Down gaze\n* Extraocular movement:\n\n  o Extraocular movement of over-action or under-action of equal or greater than 0.5 in any of the nine cardinal positions of gaze\n* Confrontational Visual field:\n\n  o Abnormal monocular visual field on confrontational visual field test\n* Hess chart test o Abnormal or asymmetry in pattern of extraocular muscle action in Hess chart test","59 Years",{"count":174,"type":22},30,"OBSERVATIONAL","The assessment and monitoring of the field of binocular single vision remains a crucial aspect of ophthalmological care, yet current clinical practice relies on normative standards established by Feibel \\& Roper-Hall in 1974 that present significant limitations for contemporary application. The original study, conducted with a demographically homogeneous Caucasian population in St Louis using only \"several\" normal individuals, raises concerns regarding its applicability to Asian populations, particularly in Singapore, where ethnic and genetic factors may influence ocular characteristics. The limited sample size significantly increases the likelihood of Type II errors, whilst the temporal gap of over five decades introduces additional concerns regarding population changes, environmental factors, and advances in measurement techniques that have not been incorporated into current normative data. Given these substantial limitations in demographic representation, statistical power, and temporal relevance, there exists a pressing need to establish population-specific normative data for the field of binocular single vision in Singapore's adult population, which would provide more clinically relevant reference values and potentially improve diagnostic accuracy for ocular conditions in the local context.",[178],"Binocular Visual Function",[180],"Binocular field of vision","2026-01-07",{"date":183,"type":40},"2026-01-09",{"date":185,"type":40},"2025-10-15",{"date":187,"type":22},"2026-10-14",{"name":46,"class":47},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":196,"maxAge":19,"enrollmentInfo":197,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":48},"100618968","user-centric-study-of-patients-receptiveness-towards-the-web-based-automated-vision-impairment-gaze-tracking-analysis-systems-100618968","NCT07338513","User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems","AVIGA-SURVEY","Inclusion Criteria:\n\n1. Subjects in the age group ≥ 55 to 99 years old.\n2. Both genders\n3. Able to understand verbal spoken instructions in British\u002FAmerican English, Chinese or Bahasa Melayu and demonstrate device functionality and implementation.\n4. Subjects undergoing treatment for Wet-AMD without any signs and symptoms of recurrence of active AMD (AMD recurrence: choroidal neovascularisation, intraretinal or subretinal fluid is present) with OCT lesion fluid volume more than 2mm2 or ILM height more than 300µm.\n5. Ability to comply with the study protocol, in the investigator's judgment.\n6. Subjects must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments.\n\nExclusion Criteria:\n\n1. Unable to understand verbal spoken instructions and demonstrate device functionality and implementation.\n2. Unable to turn on and connect their computer to the AVIGA platform independently.\n3. Any ocular surgery in the previous 3 months, or vitrectomy in the previous 12 months\n4. Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye\n5. Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study\n6. Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye.\n7. History of idiopathic or autoimmune-associated uveitis in either eye\n8. Active ocular inflammation or suspected or active ocular or periocular infection in either eye.\n9. Severe cognitive impairment, comorbid conditions severely limiting participation (e.g., advanced hearing loss)","55 Years",{"count":174,"type":22},"Age-Related Macular Degeneration (AMD) is the leading cause of central vision loss among older adults worldwide. Patients with AMD often require frequent monitoring of visual function and disease progression, typically through multiple follow-up visits involving optical coherence tomography (OCT), visual acuity testing (VA), and clinical consultations.\n\nWhile digital self-monitoring tools have emerged as promising solutions to reduce the burden of in-clinic visits, many elderly patients face challenges in engaging with these platforms due to visual impairment, limited digital literacy, and poorly optimised user interfaces. These barriers may reduce patient willingness to adopt such systems and undermine their long-term effectiveness.\n\nTo address this gap, the study team has developed the web-based AVIGA (Automated Vision Impairment Gaze-tracking Analysis) system, which is a portable, self-administered, home-based digital monitoring system designed to minimise cognitive load and maximise usability for elderly AMD patients. The platform integrates patient-centred design principles such as simplified navigation, optimised text, and multimodal feedback (visual and audio) to empower users to independently track their visual health.\n\nA prospective, single-site usability trial to evaluate the AVIGA platform using validated human factors measures: the System Usability Scale (SUS), the Technology Acceptance Model (TAM) will be conducted. By examining the relationship between usability, cognitive load, and perceived empowerment, this study aims to identify critical user interface and user experience (UI\u002FUX) design factors that influence willingness to adopt and sustain use of digital health tools among elderly AMD patients.",[200,201],"Age-Related Macular Degeneration","Wet Age-related Macular Degeneration",[203,204,205,206],"user interface","user experience","Technology Acceptance Model","System Usability Scale","2026-01-05",{"date":209,"type":40},"2026-01-14",{"date":211,"type":22},"2026-01",{"date":213,"type":22},"2027-09",{"name":46,"class":47},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":237,"locationsCount":48},"100522002","brain-computer-interface-bci-integrated-wearable-hand-robotic-glove-system-for-upper-limb-stroke-rehabilitation-100522002","NCT06076928","Brain Computer Interface (BCI) Integrated Wearable Hand Robotic Glove System for Upper Limb Stroke Rehabilitation","Brain Computer Interface (BCI) Integrated Wearable Hand Robotic Glove System for Upper Limb Stroke Rehabilitation: A 3-arm Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 21-85 years, males and females\n2. First diagnosis of stroke (ischemic or haemorrhagic), confirmed by neurologist\u002Fneurosurgeon\u002FCT\u002FMRI imaging\n3. \\> 16 weeks post stroke\n4. Hemiplegic pattern of post-stroke weakness\n5. MRC ≥ 2\u002F5 motor power and above for shoulder abduction \\& elbow flexion\n6. MRC 0 to 4\u002F5 motor power and above for finger flexors \\&\u002For extensors of thumb, index, middle fingers\n7. Screening Fugl-Meyer wrist hand sub score \\\u003C18\u002F24\n8. Spasticity MAS \\\u003C3 for thumb, index, and middle fingers\n9. Able to discriminate thumb and index sensation to pain\n10. Hand sizes within 170-200mm (length) \\&75-85mm (width), compatible with HandyRehab robotic glove\n11. BCI compatible brain states using a standardised screening protocol\n12. Able to understand simple commands with Mini Mental state examination scores MMSE \\> 21\u002F30)\n13. Able to give informed consent\n\n    * Subjects who are unable to clear BCI screening 11. will be randomised to either CT or HR groups.\n\nExclusion Criteria:\n\nNeurological\n\n* Recurrent stroke\n* Diagnosis of neurodegenerative disease; e.g. Parkinson's' disease, Dementia, ALS\n\nMedical:\n\n\\- unstable medical or neurological conditions, life expectancy \\\u003C6 months, end-organ renal failure on dialysis, severe heart failure, postural hypotension, history of uncontrolled sepsis, epilepsy with seizure within 3 months of informed consent, skin conditions which could potentially be worsened by wearable robot (ulcers, open wounds, eczema, infections etc)\n\nPostural:\n\n* Unable to tolerate upright posture or sit unaided for \\\u003C 90min with rest breaks\n* Cognitive\u002Fbehavioural\u002Fvisual:\n* Severe dysphasia\u002Faphasia, severe visual neglect\u002Fblindness, untreated severe depression, psychiatric illness, unable to understand study requirements\n\nUpper limb:\n\n* Moderate to severe spasticity (Modified Ashworth scale MAS ≥2)\n* Hand\u002Farm related pain (VAS Pain ≥ 5\u002F10),\n* Presence of finger contractures, reduced functional range of motion, limiting functional wrist\u002Ffinger movements, active fractures or arthritis with deformities\n* Severe limb ataxia\u002Fapraxia\n* Severe post stroke hemi-anaesthesia in affected UE\n\nBCI incompatibility:\n\n* Motor imagery EEG signals unable to be detected\n* Presence of craniectomy skull defect (affecting BCI cap fit and electrode contact)\n* Concomitant participation in other interventional research trials\n* Resident of nursing home or overseas country which may compromise attendance at research site\n* Pregnant or lactating females will not be allowed to participate","85 Years",{"count":21,"type":22},[25],"Upper extremity (UE) recovery remains a huge rehabilitation challenge with largely incomplete recovery of the upper limb post stroke. This is due to heavier priorities placed on other stroke competencies such as mobility, activities of daily living training and home integration which results in suboptimal amounts of time spent in upper limb training post stroke.\n\nIn this study the investigators plan to pilot brain computer interface (BCI) integrated wearable hand robotic glove (HandyRehab) system for upper limb stroke rehabilitation.",[227],"Stroke",[229,230],"Brain Computer Interface","Hand exoskeleton robot","2025-09-02",{"date":233,"type":40},"2025-09-09",{"date":235,"type":40},"2024-08-01",{"date":211,"type":22},{"name":46,"class":47},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":48},"100604608","use-of-anodal-tdcs-to-enhance-upper-limb-recovery-in-stroke-100604608","NCT07151729","Use of Anodal tDCS to Enhance Upper Limb Recovery in Stroke","Use of Anodal Transcranial Direct Current Stimulation to Enhance Upper Limb Recovery in Stroke","Inclusion Criteria:\n\n* First ever unilateral ischaemic or haemorrhagic stroke, as documented by CT or MRI scans\n* Age 21-80 years, both males and females\n* Within 8 weeks of stroke onset\n* Severe weakness of one upper limb, defined by a Shoulder Abduction and Finger Extension (SAFE) score \\\u003C 5 (Medical Research Council grading)\n* Provision of informed consent by patient or a legal guardian in accordance with the local ethics committee guidelines and the Declaration of Helsinki\n\nExclusion Criteria:\n\n* Bilateral hemispheric or cerebellar strokes\n* Pre-existing arm pathology (e.g. contracture, severe pain, etc.) on the affected side\n* Presence of brain implants, and previous insertion of external ventricular drains.\n* Metallic implants at the level of the neck, mouth cavity and below are permitted (e.g. Cardiac stents, dental implants, pacemakers and other metallic objects)\n* A history of spontaneous seizures, epilepsy, brain tumour, and cranial surgery\n* Severe cognitive impairment (MOCA Score \\\u003C10) that would hinder sufficient understanding of the instructions\n* Pregnancy","80 Years",{"count":247,"type":22},50,[25],"This will be a randomized, blinded, sham-controlled trial. The medical device used, Soterix Medical 1x1 tDCS stimulator, is capable of delivering either real or sham tDCS and has been used in many randomised controlled trials in stroke patients.\n\n50 patients with subacute stroke and severe upper limb weakness within 8 weeks of stroke on transfer to TTSH stroke rehab wards will be recruited over a period of 10 months. Recruited patients will be randomized into the intervention and control arms in a 1:1 ratio.",[227],[252,253,254],"stroke","tdcs","upper limb","2025-08-25",{"date":257,"type":40},"2025-09-03",{"date":259,"type":22},"2025-09-01",{"date":261,"type":22},"2026-12-31",{"name":46,"class":47},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":288,"locationsCount":48},"100592833","using-social-influencers-for-public-health-education-on-antibiotic-use-and-antimicrobial-resistance-100592833","NCT06998576","Using Social Influencers for Public Health Education on Antibiotic Use and Antimicrobial Resistance","Different Strokes for Different Folks - Leveraging on Social Networks for Public Health Education on Antibiotic Use and Antimicrobial Resistance","Inclusion Criteria:\n\n* Adults aged 21 years and above\n* Patrons of the 30 participating healthcare clinics, food and beauty establishments\n\nExclusion Criteria:\n\n* Patrons who are already enrolled in the study at one of the 30 participating establishments",{"count":271,"type":22},3300,[25],"This study aims to compare the effectiveness of health education facilitated by neighborhood food and beauty establishments with that facilitated by clinics in increasing the public's knowledge of antibiotic use and antimicrobial resistance (AMR) and improving antibiotic behaviors.\n\nThe quasi-experimental study will involve a total of 3300 patrons of the 10 most popular consenting clinics, food and beauty establishments respectively, in two neighborhoods in Singapore.\n\nRecruitment Process\n\n1. Participants will scan the QR code on the posters in the participating clinics\u002Festablishments\n2. Read the study information sheet\n3. Consent will be implied on submission of survey\n4. Total recruitment period: One year\n5. Target: 3300 patrons of the 30 establishments (10 each of clinics, food, and beauty establishments)\n\nIntervention Structure\n\n1. Participants will complete a pre-intervention\u002Fbaseline survey (#1)\n2. Intervention includes an animated educational video with key messages on appropriate antibiotic use and AMR\n3. Followed by immediate post-intervention survey (#2)\n4. Provide contact details (mobile phone number) for reimbursement \\& future follow-up online surveys\n5. Complete follow-up online surveys: at 1 month post-intervention (#3), 3 months post-intervention (#4) and 6 months post-intervention (#5)\n\nExpected Outcomes Increase in public knowledge of antibiotic use and AMR, and antibiotic behaviors through health education facilitated by neighborhood food and beauty establishments, in addition to that facilitated by clinics",[275],"Community Members",[277,278,279,280,281],"public health education","antimicrobial resistance","antibiotic use","animated educational video","neighborhood establishments","2025-07-28",{"date":284,"type":40},"2025-07-29",{"date":286,"type":40},"2025-07-21",{"date":104,"type":22},{"name":46,"class":47},{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":88,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":4},"100598957","examining-nurses-trust-and-acceptance-of-fair-an-ai-powered-falls-risk-recommender-100598957","NCT07078240","Examining Nurses' Trust and Acceptance of FAIR, an AI-powered Falls Risk Recommender","\"You Sure or Not?\" Examining the Trust, Acceptance and Adoption of Falls Risk - Artificial Intelligence Recommender (FAIR) System by Nurses","Inclusion Criteria:\n\n* Practicing nurse involved in falls risk assessments of patients\n\nExclusion Criteria:\n\n\\-",{"count":21,"type":22},[25],"An exploratory mixed-method study will be conducted to test acceptance and trust of an AI-powered falls risk predictor system by inpatient hospital nurses",[300],"Falls Risk",[302,303,304],"Artificial Intelligence trust","Artificial Intelligence acceptance","Artificial Intelligence",{"date":306,"type":40},"2025-07-22",{"date":308,"type":22},"2027-01-01",{"date":310,"type":22},"2029-06-30",{"name":46,"class":47},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":88,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":328,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":48},"100599926","evaluating-the-effectiveness-and-implementation-of-caregiver-support-initiatives-for-caregivers-of-older-patients-in-singapore-100599926","NCT07090837","Evaluating the Effectiveness and Implementation of Caregiver Support Initiatives for Caregivers of Older Patients in Singapore","Project Carer Matters 2: Evaluating the Effectiveness and Implementation of Caregiver Support Initiatives for Caregivers of Older Patients in Singapore","PCM2","Inclusion Criteria:\n\n* 21 years of age and above\n* Main or secondary caregiver of an older person receiving home-based care\n* Able to read and converse in English\n* Has a mobile smartphone and is able to navigate basic functionalities on mobile apps\n\nExclusion Criteria:\n\n* Participants who are cognitively impaired\n* Unwilling to download and utilise app\n* Unable to read or converse in English comfortably",{"count":321,"type":22},400,[25],"We are evaluating the caregiver support initiatives at a tertiary hospital in Singapore (Tan Tock Seng Hospital - TTSH) provided to caregivers caring for older patients.\n\nThe evaluation will focus on 1) evaluating the process \u002F delivery \u002F implementation of these initiatives to caregivers and 2) the outcomes of caregivers and their care recipients after receiving these caregiver support services at TTSH. Research questions are as follows:\n\nProcess evaluation:\n\n1. How are the bundle(s) of caregiver support initiatives at TTSH delivered to caregivers?\n2. What and how was impact achieved for these initiatives?\n\n   Outcome evaluation:\n3. Did caregivers (and patients) benefit from these support initiatives and how?\n4. Which aspects of the caregiver support initiatives are most beneficial to caregivers (and patients)?\n\nEligible caregivers will be invited to take part in the study and to complete 3 surveys and an optional interview over the period of their care recipients' hospital stay at TTSH, and 2 months after discharge. During their care recipients' stay, they may be introduced to any of the caregiver support initiatives, based on their needs. Caregivers enrolled in this study will take part in 3 surveys - 1 conducted at the beginning of care recipients' hospital stay, 1 conducted around the discharge period and 1 conducted one month after discharge. The aim of the surveys is to find out if caregivers have attended or used any of these services and whether they benefited from them.",[325,326,327],"Caregiver","Caregiver Stress","Caregiver Resilience and Stress",[325,329,330,331,332],"Caregiver burden","Caregiver stress","Digital health","Caregiver support",{"date":284,"type":40},{"date":335,"type":40},"2025-05-08",{"date":337,"type":22},"2027-05",{"name":46,"class":47},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":245,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":359,"locationsCount":48},"100547766","an-exploratory-study-of-a-wearable-robotic-hand-orthosis-100547766","NCT06412237","An Exploratory Study of a Wearable Robotic Hand Orthosis","An Exploratory Study of a Wearable Robotic Hand Orthosis in the Chronic Stroke Population in Singapore: A Clinic to Home Feasibility Trial","Inclusion Criteria:\n\n* Patient with first ever clinical stroke (ischaemic or haemorrhagic) with hemiplegic motor deficit(s) due to stroke as diagnosed by CT or MRI.\n* Post stroke of at least 6 months with stable neurological status.\n* Age 21 to 80 years of age.\n* Hemiplegic pattern and shoulder abduction MRC motor power \\> 2\u002F5 and elbow extension \\>2\u002F5\n* Has a stable home abode and a carer\u002FNOK to assist with donning of device and supervise home based exercise\n* MOCA \\> or equal to 22\u002F30\n* Able to give and sign informed consent at research site.\n* Able to speak English\n\nExclusion Criteria:\n\n* Non-stroke related causes of arm motor impairment.\n* Has unstable or terminal medical conditions which may affect participation (e.g.: unresolved sepsis, postural hypotension, end stage renal failure, cancer, retroviral disease, on immunosuppressive therapy) or anticipated life expectancy of \\\u003C1 year due to malignancy or neurodegenerative disorder.\n* Local factors which may be worsened by intensive arm therapy: spasticity of Modified Ashworth Scale grades 3-4, skin wounds, shoulder pain Pain Scale \\>5\u002F10, active\u002Fnon-united fractures or arthritis or fixed joint\u002Ftissue flexion contractures of shoulder, elbow, wrist or fingers incompatible with tenoexo interface.\n* Patient with severe cognitive, perceptual (include hemi-neglect), and\u002For emotional-behavioural issues that preclude participation.\n* Experiencing moderate to severe levels of pain (Numerical Vertical Pain Scale \\> 5).\n* Is pregnant or breast feeding. Neither the tenoexo nor the IMUs have been tested to evaluate the usage with pregnant and\u002For breast feeding mothers. Further, due to the length of the study, pregnancy may make it difficult to follow the study schedule.\n* Have a pacemaker. Magnets are used throughout the system.",{"count":347,"type":22},20,[25],"Upper limb deficits usually remain in 75% of the stroke survivors despite completing full rehabilitation. This is due to lack of effectiveness of rehabilitation and the degree of support and resources available.\n\nIn this study, the investigators plan to study the use of assistive technologies in chronic stroke survivors.",[227],[230,352],"Robotic hand orthosis","2025-04-10",{"date":355,"type":40},"2025-04-15",{"date":357,"type":40},"2024-06-01",{"date":211,"type":22},{"name":46,"class":47},{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":245,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":379,"locationsCount":48},"100547330","a-qualitative-and-usability-evaluation-of-advanced-technologies-for-home-upper-limb-neurorehabilitation-post-stroke-100547330","NCT06406569","A Qualitative and Usability Evaluation of Advanced Technologies for Home Upper Limb Neurorehabilitation Post-stroke","Home RehabGym: a Qualitative and Usability Evaluation of Advanced Technologies for Home Upper Limb Neurorehabilitation Post-stroke","Home RehabGym","Inclusion Criteria:\n\n1. Clinical stroke (ischaemic or haemorrhagic) confirmed by admitting doctors and CT, CT angiography or MRI brain imaging\n2. Age 21 to 80 years, both males and females\n3. At least 28 days post-stroke\n4. Upper limb motor impairment of Fugl-Meyer Assessment (FMA) scale 20 to 50\n5. Montreal Cognitive Assessment (MoCA) \\> 21\u002F30\n6. Ability to sit supported and continuously for 60 minutes\n7. Stable home abode with enough space to place technologies\n8. Has a carer\u002Fnext of kin to supervise home-based exercises\n\nExclusion Criteria:\n\n1. Functional impairment of the upper limb due to other pathologies\n2. Medical conditions incompatible with research participation: uncontrolled medical illnesses (hypertension or diabetes, ischaemic heart disease, congestive heart failure, bronchial asthma, severe \u002Funtreated depression, agitation, end stage renal\u002Fliver\u002Fheart\u002Flung failure, unresolved cancers)\n3. Anticipated life expectancy of less than 6 months\n4. Pacemakers and other active implants\n5. Active seizures within 3 months\n6. Local factors potentially worsened by intensive technology-aided upper-limb therapy and computer-based training:\n\n   * Spasticity - modified Ashworth Scale MAS \\> 2 of any upper limb muscle groups\n   * Severe pain in affected arm - Visual Analogue Scale for pain VAS \\> 5\u002F10\n   * Skin wounds\n7. Cognitive impairment precluding study participation\n8. Severe visual impairment or visual neglect affecting ability to use technologies\n9. History of dementia, depression or behavioural problems\n10. Pregnant or lactating females will not be allowed to participate",{"count":174,"type":22},[25],"Due to limited resources such as the low therapist to patient ratio or high costs associated to rehabilitation therapy, providing higher therapy dose to patients after discharge is highly challenging. This often results in non-use of the impaired limb as a result of the decreased therapy dose, causing partial loss of the functional improvements previously gained during early rehabilitation.\n\nIn this study, the investigators plan to pilot the HomeRehab Gym concept via the deployment of three rehabilitation devices at patients' homes: MyoPanda, H-Man and ReHandyBot.",[227],[373,374],"Technology-aided","Upper limb rehabilitation",{"date":355,"type":40},{"date":377,"type":40},"2024-07-31",{"date":211,"type":22},{"name":46,"class":47},{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":48},"100464064","tracking-of-upper-limb-sensory-and-motor-recovery-in-asian-stroke-survivors-100464064","NCT05322837","Tracking of Upper Limb Sensory and Motor Recovery in Asian Stroke Survivors","Deep Phenotyping of Upper Limb Sensori-motor Recovery in Asian Stroke Survivors: Concept, Development and Implementation of a Rehabilomics-driven Technology-assisted Data Platform","Inclusion Criteria:\n\n1. Stroke confirmed by neurologists, neurosurgeons and brain imaging (CT, CT angiogram, MRI, MR angiogram)\n2. First ever confirmed stroke\n3. Asian ethnicity\n4. Age 21-90 years\n5. Montreal Cognitive Assessment (MOCA) scores 21\u002F30 and above\n6. Admission to rehabilitation ward is within 8 weeks of stroke onset\n\nExclusion Criteria:\n\n1. Recurrent stroke or transient ischaemic attack (TIA)\n2. Upper limb impairment not related to stroke: e.g., subarachnoid haemorrhage, traumatic brain injury or brain tumours\n3. Bilateral upper limb impairment.\n4. Uncontrolled medical conditions such as hypertension, hypotension, diabetes mellitus, unstable angina, cardiac failure or sepsis will be excluded.\n5. Active fractures or arthritis of upper limb joints\u002Fbones\n6. Visual Analogue Scale (VAS) pain \\> 5\u002F10\n7. MOCA \\\u003C 21\u002F30\n8. Severe behavioural disturbance or agitation or epilepsy or untreated depression\n9. Life expectancy \\\u003C 6 months\n10. End organ failures on replacements (renal dialysis or renal replacement therapies)\n11. Minimally responsive or unresponsive awareness (vegetative) states\n12. Pregnancy or lactation states\n13. Admission to rehab ward later than 8 weeks post-stroke\n14. (For TMS assessments only) History of epilepsy or seizures, or cranial surgeries, or have metal implants in body or head, or have implanted electronics, or have metallic valve, or skull fracture or brain injury, or head or brain surgeries.","90 Years",{"count":321,"type":22},"As Singapore's population is aging rapidly, the incidence rate of stroke has been increasing in the past years. Rehabilitation is essential for the resumption of daily activities, and with the appropriate care, it is possible for stroke-survivors to regain most of their functions.\n\nHence, this study aims to better understand upper limb recovery covering different stages post-stroke in a representative cohort of Asian adults",[227],{"date":355,"type":40},{"date":393,"type":40},"2023-04-26",{"date":211,"type":22},{"name":46,"class":47},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":387,"enrollmentInfo":404,"targetDuration":4,"studyType":23,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":48},"100536871","telerehabilitation-robotics-for-upper-limb-rehabilitation-after-stroke-100536871","NCT06270459","Telerehabilitation Robotics for Upper Limb Rehabilitation After STroke","Telerehabilitation Robotics for Upper Limb Rehabilitation After STroke (TRUST): a Study of Multi-cluster Adoption","TRUST","Inclusion Criteria:\n\n1. Clinical stroke (ischaemic or haemorrhagic) confirmed by admitting doctors and CT, CT angiography or MRI brain imaging.\n2. Age 21 to 90 years, both males and females.\n3. At least \\> 28 days post stroke.\n4. Upper limb motor impairment of Fugl-Myer Motor Assessment (FMA) scale 10 to 60\n5. Has a stable home abode and a carer\u002F NOK to supervise home based exercise.\n6. Ability to sit supported continuously for 60 minutes.\n7. Montreal Cognitive Assessment (MOCA) score \\> 21\u002F30\n8. Able to understand purpose of research and give consent.\n\nExclusion Criteria:\n\n1. Non-stroke related causes of arm motor impairment.\n2. Medical conditions incompatible with research participation: uncontrolled medical illnesses (hypertension or diabetes, ischaemic heart disease, congestive heart failure, bronchial asthma, end stage renal\u002Fliver\u002Fheart\u002Flung failure, unresolved cancers.\n3. Anticipated life expectancy of \\\u003C 6 months.\n4. Inability to tolerate sitting continuously for 60 minutes.\n5. Local factors potentially worsened by intensive robot-aided arm therapy and computer-based training: active seizures within 3 months, spasticity of Modified Ashworth Scale grades \\>2 skin wounds, shoulder, arm pain VAS \\> 5\u002F10, active upper limb fractures, arthritis, fixed upper limb flexion contractures.\n6. Hemianesthesia of affected limb.\n7. History of dementia, severe depression, agitation, or behavioural problems.\n8. Pregnancy or lactation in females\n9. Absence of reliable carer to provide supervision during home training",{"count":405,"type":22},54,[25],"There has been an observed decrease in motor and functional ability and non-use of the impaired limb in chronic patients. This is due to the immediate drop in intensive daily therapy (5 days per week for 3 hours\u002Fday) that is usually provided during the inpatient (acute) phase upon discharge from the hospital.\n\nIn this study, the investigators plan to address the low dosage of therapy in the post-acute discharge phase for stroke survivors.",[227],"2025-04-08",{"date":411,"type":40},"2025-04-11",{"date":413,"type":40},"2024-11-01",{"date":415,"type":22},"2025-08-14",{"name":46,"class":47},{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":222,"enrollmentInfo":424,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":425,"conditions":426,"keywords":427,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":48},"100530491","longitudinal-multimodal-profiling-of-balance-and-gait-in-stroke-100530491","NCT06187467","Longitudinal Multimodal Profiling of Balance and Gait In Stroke","Longitudinal Multimodal Profiling of Balance and Gait In Stroke Using EEG and Lower Limb Sensors: A Feasibility Study.","Inclusion Criteria:\n\n* First-ever clinical stroke (ischaemic or haemorrhagic) confirmed by admitting doctors brain imaging\n* Age 21 to 85 years\n* At least ≥ 30 days post-stroke\n* Gait impairments related to stroke\n* Functional ambulation category -6 levels (Mehrholz et al, 2007): FAC ≥ 4, i.e. able to ambulate independently on level surface but requires supervision to negotiate (e.g. stairs, inclines, non-level surfaces).\n* Montreal Cognitive Assessment (MoCA) score \\> 21 (Nasreddine et al., 2005)\n* Able to understand study instructions and requirements\n\nExclusion Criteria:\n\n* Non-stroke related causes of gait impairment\n* Medical conditions incompatible with research participation: uncontrolled medical illnesses (hypertension or diabetes, ischaemic heart disease, congestive heart failure, bronchial asthma, severe \u002Funtreated depression, agitation, end stage renal\u002Fliver\u002Fheart\u002Flung failure, dialysis, unresolved cancers e.g.,), active seizures within 3 months\n* Anticipated life expectancy of \\\u003C 6 months\n* On subcutaneous or oral anti-coagulation\n* Local factors potentially worsened by gait training: joint and muscle pains\n* Lower limb pain VAS \\>4\u002F10, active lower limb fractures or arthritis, fixed leg contractures, severe peripheral vascular disease, organomegaly or aortic aneurysms\n* Active unhealed skin wounds or inflammatory skin conditions over trunk and lower limbs,\n* Severe visual impairment or visual neglect affecting navigation\n* Known allergy to EEG gel (Recoverix)\n* Presence of craniectomy skull defect\n* Resident of nursing home or overseas country which may compromise attendance at research site\n* Pregnant or lactating females",{"count":174,"type":22},"Balance and gait recovery is a critical aspect of post-stroke motor rehabilitation. Researchers have effectively utilized EEG to investigate different aspects of lower limb motor control, however there are several technical challenges in the existing brain computer interface (BCI) motor profiling.\n\nThe study aims to test the EEG-BCI system to see if it's effective in understanding the balance and walking patterns of post-stroke populations.",[227],[428,429],"Electroencephalographic (EEG)","Brain Computer Interfaces",{"date":411,"type":40},{"date":432,"type":40},"2024-07-01",{"date":434,"type":22},"2025-10",{"name":46,"class":47},{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":446,"conditions":447,"keywords":451,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":48},"100521708","targeting-osteosarcopaenia-and-multimorbidity-for-frailty-prevention-100521708","NCT06073106","Targeting Osteosarcopaenia and Multimorbidity for Frailty Prevention","Targeting Osteosarcopaenia and Multimorbidity for Frailty Prevention Through Identification and Deep Phenotyping Methods in Healthy Aging and High-burden Disease Cohorts.","OPTIMA-C","Inclusion Criteria:\n\n1. Age ≥ 50y\n2. Asian ethnicity\n3. First diagnosis (stroke, Traumatic Brain Injury (TBI), knee osteoarthritis, breast cancer)\n4. Living in community\n5. Able to understand 1 step simple commands\n6. For inpatients: (i) within 12 weeks of disease (stroke\u002FTBI) onset, and (ii) within 2 weeks of rehabilitation ward admission\n7. For outpatients: (i) \\>6 months from initial diagnosis of first stroke, TBI, knee osteoarthritis or breast cancer, and (ii) at least standby assistance, modified independent or independent in ambulation with \u002Fwithout walking.\n\nExclusion Criteria:\n\n1. Nursing home or dormitory resident\n2. Non-resident status in Singapore (e.g. foreign worker, tourist, temporary visit pass)\n3. Impairments affecting understanding of questionnaires and tasks: e.g. severe deafness, severe visual impairment and severe \u002Fglobal aphasia,\n4. Presence of active fractures, dislocations, non-weight bearing status, burns, unhealed wounds, active skin infections\u002Feczema and agitated behaviour or delirium\n5. Anticipated life expectancy \\\u003C 1 year\n6. Presence of tracheostomy, ventilator, renal dialysis, end-organ failure\n7. Patients with disorders of consciousness.\n8. Pregnant or lactating participants\n\n   For Knee Osteoarthritis patients only:\n9. Alternative diagnosis to knee OA e.g. Referred pain from hip or spine.\n10. Other forms of knee arthritis eg. Inflammatory, post traumatic\n11. Previous knee arthroplasty",{"count":445,"type":22},500,"The aging population and its accompanying burden from non-communicable chronic diseases predicts an increasing impact imposed by frailty on healthcare systems. This is due to a lack of normative data for older adults and reliable risk stratification methods to develop effective approaches to the prevention of frailty.\n\nIn this study, the investigators plan to form a common dataset for phenotype identification, risk stratification of frailty and its targeted treatment plans in the at-risk and mildly frail population.",[227,448,449,450],"Traumatic Brain Injury","Knee Osteoarthritis","Breast Cancer",[452,453,454],"Frailty","Multimorbidity","Osteosarcopaenia",{"date":411,"type":40},{"date":457,"type":40},"2025-01-01",{"date":459,"type":22},"2027-01",{"name":46,"class":47},{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":19,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":475,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":488,"locationsCount":48},"100554544","pillsense-for-suspected-upper-gastrointestinal-bleeding-100554544","NCT06500468","PillSense for Suspected Upper Gastrointestinal Bleeding","Usage of Novel Blood Sensing Capsule in Emergency Department to Triage Patients With Suspected Upper Gastrointestinal Bleeding","BLEED","Inclusion Criteria:\n\n* Males or females aged 21 years and above and are able to give consent.\n* Patients who are willing and able to comply with the study protocol (including undergoing endoscopy)\n* Presented to Emergency Department with symptoms of acute overt upper gastrointestinal bleeding such as coffee ground vomiting and melena (but without melaena on physical examination)\n\nExclusion Criteria:\n\n* Patients who had hemodynamic shock (systolic blood pressure below 90 mm Hg and pulse rate over 120\u002Fmin)\n* Patients who presented with fresh hematemesis, hematochezia and\u002For melaena\n* Patients requiring urgent endoscopy \u002F surgery at time of review or already planned for admission by ED physician for non UGIB related indications\n* Patients who had conditions that might contraindicate the use of an ingestible capsule, such as capsule endoscopy (eg. Dysphagia, odynophagia, swallowing disorder, and\u002For Zenker's diverticulum, issues with the motility of the gastrointestinal tract, Crohn's disease, previous GI surgery, suspected ileus, bowel obstruction and\u002For perforation)\n* Patients with a known history of oesophageal or gastric varices\n* Patients with known UGI pathology (such as oesophageal\u002Fgastric cancer), or recent (within 3 months) upper GI ulcer bleeding, upper GI surgeries or procedures\n* Patients who are on anticoagulation\n* Patients with cardiac implantable electrical device (CIED)\n* Patients who had altered mental status\n* Pregnant and\u002For lactating women (Female patients below age 60, without history of hysterectomy or are not documented to be post-menopausal, will be given a urine pregnancy test to confirm they are not pregnant)\n* Patients who have an MRI investigation planned within 2 weeks",{"count":470,"type":22},84,[25],"This study aims to evaluate the efficacy and safety of a novel blood sensing capsule (PillSense), to help emergency doctors better evaluate if patients have active upper digestive tract bleeding, to determine if they can be discharged safely. The PillSense System consists of the PillSense Capsule, a small single use capsule that is safe for human consumption and PillSense Receiver, an external real-time monitor for data display to detect the presence of bleeding in the upper digestive tract within 10 minutes.",[474],"Bleeding Ugi",[476,477,478,479,480,481],"capsule endoscopy","upper gastrointestinal bleeding","melena","coffee ground vomitting","emergency department","triage","2024-12-05",{"date":484,"type":40},"2024-12-10",{"date":486,"type":40},"2024-07-18",{"date":211,"type":22},{"name":46,"class":47},{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":23,"phases":498,"briefSummary":499,"conditions":500,"keywords":504,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":48},"100558612","the-gos-frail-geriatric-oncology-supportive-care-for-frail-older-adults-with-cancer-study-100558612","NCT06553378","The GOS-Frail (Geriatric Oncology Supportive Care for Frail Older Adults With Cancer) Study","GOS-Frail","Inclusion criteria\n\n1. Age ≥ 65\n2. Diagnosis of solid organ cancer\n3. Plan for curative-intent chemotherapy and\u002For radiotherapy\n4. Clinical Frailty Scale (CFS) score ≥ 4,\n\nExclusion criteria: Evaluation by Geriatric or Palliative Medicine in the previous 6 months.",{"count":497,"type":22},154,[25],"Background Cancer is more prevalent in older adults, but most cancer treatment trials have mainly involved young and healthy subjects. Among geriatric syndromes, frailty is a significant risk factor for negative outcomes such as treatment delays, discontinuation, and treatment-related side effects, as well as functional decline and poor survival. Research has shown that geriatric assessment with appropriate intervention can improve these outcomes, although the impact may be influenced by the inclusion of patients receiving palliative-intent treatment. Supportive care focuses on symptom assessment and treatment to enhance treatment tolerance and quality of life. To date, there have been no studies examining the combined benefits of geriatric oncology and supportive care clinics. We conducted a pilot study called Geriatric Oncology Supportive Clinic for Elderly (GOSPEL), which demonstrated an improved quality of life for older adults with curable cancer. Based on these results, we developed an enhanced care model.\n\nAim The study GOS-Frail aims to assess the effect of an integrated Geriatric Oncology Supportive Clinic on the quality of life of older adults with cancer receiving curative-intent chemotherapy and\u002For radiotherapy at 1 month.\n\nMethods The GOS-Frail study is a multi-centre, open-label, parallel-arm, randomized controlled trial conducted in the specialist outpatient clinics of two university-affiliated tertiary care hospitals. 154 adults aged 65 and above, diagnosed with solid organ cancer and planned for curative-intent chemotherapy and\u002For radiotherapy, and with a clinical frailty scale score of 4 and above, will be recruited. Subjects will be randomized to either attend a geriatric oncology supportive clinic or receive frailty education material. Quality of life questionnaires will be administered at baseline, 2 weeks, and 1, 3, 6, and 12 months from treatment initiation.\n\nHypothesis:\n\nThe GOS-Frail study investigates on the role of a synergistic geriatric oncology and supportive model of care in improving quality of life in older adults undergoing curative-intent cancer treatment.",[501,502,503],"Geriatric Oncology","Supportive Care","Quality of Life",[501,502,503],"2024-08-13",{"date":507,"type":40},"2024-08-14",{"date":509,"type":22},"2024-09-01",{"date":511,"type":22},"2027-08-31",{"name":46,"class":47},{"id":514,"slug":515,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":520,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":533,"leadSponsor":535,"locationsCount":4},"100557583","development-and-validation-of-an-automated-self-administered-visual-acuity-system-100557583","NCT06540001","Development and Validation of an Automated Self-administered Visual Acuity System","AutoVA","Inclusion Criteria:\n\n1. Patients age \\>21 and able to give consent\n2. Patients who have at least counting finger vision\n3. Patients who is able to speak in an audible and clear voice\n4. Patients who is able to use a digital device independently (e.g. handphone)\n\nExclusion Criteria:\n\n1. Patients on wheelchair\u002F walking aids\n2. Patients with hearing difficulties\n3. Patients with speech difficulties\n4. Patients who have cognitive impairment\n5. Patients who are hemiplegic\u002F motor dysfunction\n6. Patients who have vision worse than counting fingers\n7. Patients who are pregnant","100 Years",{"count":522,"type":22},100,[25],"Visual acuity tests, commonly conducted in clinics and used for health screenings, are becoming more in demand due to an aging population. Current online self-eye check apps are limited as they don\\'t accurately reflect true distance vision assessed in clinical settings. These tests, performed by trained personnel, are time-consuming and can cause delays in clinics. This project aims to develop an automated Visual Acuity (VA) station using AI technologies like speech-to-text and computer vision, hypothesizing that it can match the accuracy of manual assessments by clinic staff, thus potentially reducing waiting times and improving efficiency.",[526],"Visual Impairment",[528],"Visual acuity","2024-08-03",{"date":531,"type":40},"2024-08-06",{"date":235,"type":22},{"date":534,"type":22},"2025-08-01",{"name":46,"class":47},""]